At CES, a wave of AI-powered health devices—from hormone trackers to smart scales—pitched big wellness benefits, but experts warned the claims outpace the science and safeguards. The FDA said it will ease oversight of “low-risk” wellness products, aligning with the Trump administration’s broader push to spur AI innovation, even as privacy advocates note HIPAA doesn’t protect most consumer health data. Startups spotlighted women’s health tools and accessibility solutions, including chatbots aimed at rural communities, while critics flagged persistent risks of biased algorithms and AI “hallucinations.” Developers said data are secure and tools fill care gaps, but civil libertarians urged consumers to treat the gadgets as aids—not substitutes—for medical professionals.
Related articles:
FDA’s General Wellness Policy for Low-Risk Devices
Ethics and governance of artificial intelligence for health
NIST AI Risk Management Framework
